SCHEMBL379339

SCHEMBL379339

CC[C@H](NC(=O)C1(c2ccccc2)CCN(C(=O)c2ccc(-c3nc(C)no3)cc2)CC1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.42
ATM Q13315 1/20 0.40
ADRB3 P13945 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SCD5 Q86SK9 1/20 0.39
TBK1 Q9UHD2 1/20 0.39
NPY2R P49146 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
KCNK3 O14649 1/20 0.38
FNTA P49354 2/20 0.38
FNTB P49356 1/20 0.38
PGGT1B P53609 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
PPARG P37231 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL378915 0.89 TSHR (0.43) TSHRATMADRB3SLC6A2SLC6A4
SCHEMBL13092253 0.86 TSHR (0.44) TSHRATMADRB3SLC6A2SLC6A4
SCHEMBL3721822 0.85 ADRB3 (0.40) TSHRADRB3SLC6A2SLC6A4TBK1
SCHEMBL13092256 0.85 TSHR (0.44) TSHRATMSCD5TBK1CA12
SCHEMBL396983 0.85 TACR1 (0.40) TSHRATMADRB3SLC6A2SLC6A4
SCHEMBL13092261 0.84 ALDH1A1 (0.42) TSHRATMADRB3SLC6A2SLC6A4
SCHEMBL13092272 0.84 TACR3 (0.42) TSHRSLC6A4SCD5CA12CA1
SCHEMBL378669 0.84 TACR1 (0.41) TSHRATMSLC6A4SCD5NPY2R
SCHEMBL13092251 0.84 BDKRB1 (0.40) TSHRATMADRB3SLC6A2SLC6A4
SCHEMBL379032 0.83 ADRB3 (0.39) TSHRADRB3SLC6A2SLC6A4TBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP claimed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 TSHR 895/4885ATM 2243/4885ADRB3 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.